PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Praxis Precision Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$260.17+18.41 (+7.61%)
Close on Oct 19, 2026
- Market cap
- $7.58B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -59.9% | -45.8% | |
| Return on assets | – | -35.2% | -42.7% | |
| Current ratio | – | 19.23 | 10.22 | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 1M | 23M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Praxis Precision Medicines generated $801.56M from operations and spent $1.60M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$801.56M
Used
$1.60M
Capital expenditure$1.60M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2137.5%
×Asset turnover0.03×
×Equity multiplier1.11×
=Return on equity, FY2024-71.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -2137.5% | 0.03× | 1.11× | -71.0% |
| FY2023 | -5037.9% | 0.02× | 1.39× | -169.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$303.27M
- Cash generatingOperating cash flow above zero-$249.07M
- Return on assets improvedROA up on the prior year-207.9% → -62.8%
- Earnings backed by cashOperating cash flow above net income-$249.07M vs -$303.27M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.77 → 10.22
- No dilutionShare count did not rise18M → 23M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.10 → 0.00